Abstract Bartter syndrome (BS) is a genetic disorder with hypokalemic metabolic alkalosis and is classified into five types. One of these, type II BS (OMIM 241200), is classified as neonatal Bartter syndrome, which is caused by mutations in the KCNJ1 gene. Transient hyperkalemia and hyponatremia are usually noted in the early postnatal period, but as type II BS is a relatively rare disease, its exact clinical course and genetic background have not yet been thoroughly characterized. This report concerns a male type II BS patient with a novel mutation in the KCNJ1 gene. The unique clinical findings of this case are that hyperkalemia (8.9 mEq/l), hyponatremia, and metabolic acidosis detected in the early postnatal period led to a diagnosis of pseudohypoaldosteronism (PHA). As an adolescent, however, the patient currently shows normal potassium levels and normal renal function, although with hypercalciuria and nephrocalcinosis, without having received any treatment. In such cases, KCNJ1 mutations should be suspected. In our case, genetic analysis of the KCNJ1 gene identified a novel homozygous 1-bp deletion mutation (c.607 del. C in exon 5).
Introduction
Bartter syndromes (BS) are inherited disorders characterized by hypokalemic metabolic alkalosis accompanied by normal or low blood pressure despite hyperreninemia and hyperaldosteronemia. Recent genetic studies have found that these diseases are caused by mutations in five genes, which lead, either directly or indirectly, to transporter or channel loss of function. The first of these genes is SLC12A1, which encodes the apical Na-K-2Cl cotransporter (NKCC2). The second is KCNJ1, which encodes the apical renal outer medullary K channel (ROMK), and the third is CLCNKB, which encodes the basolateral Cl channel Kb (ClC-Kb). The mutations of these three genes lead to type I, II, and III BS, respectively [1] [2] [3] [4] . In recent years, the fourth gene, BSND encoding barttin, a subunit for ClC-Ka and ClC-Kb, has been identified as being responsible for a combination of antenatal BS and sensorineural deafness and a phenotype now known as type IV BS [5] . Finally, a coding gene called CASR has been identified as causing type V BS, which is associated with hypoparathyroidism and is due to an increase in function mutations in the calcium-sensing receptor [6, 7] .
Patients with type I and type II BS are characterized by impaired renal concentrating capacity, saluretic polyuria, and hypercalciuria resulting in the clinical characteristics of polyhydramnios, hypo-or isosthenuria, and nephrocalci-nosis. These signs are believed to clearly differentiate these patients from those with type III BS, and the disease entity has therefore been classified as antenatal BS. In contrast to type I BS patients, type II patients usually show transient neonatal hyperkalemia and hyponatremia, and some of them also show transient metabolic acidosis. Moreover, type II BS cases show milder renal potassium loss and have minimal to normal hypokalemia compared with type I BS patients [8] .
This report describes a patient with type II BS who showed transient hyperkalemia, hyponatremia, and metabolic acidosis and who was diagnosed with pseudohypoaldosteronism (PHA) in the neonatal period but in adolescence showed normal potassium levels without having undergone any treatment.
Subject and methods

Case report
This report concerns an 18-year-old male from unrelated parents and with a sibling with normal phenotype. Polyhydramnios was detected antenataly, and he was born at 33 weeks gestation with a body weight at birth of 2,090 g (normal for gestational age). From postnatal day 2, he showed severe hyperkalemia, hyponatremia, and metabolic acidosis. In spite of treatment with glucose-insulin therapy and furosemide administration, the serum potassium level was elevated to 8.9 mEq/l on day 3. Because he also had a high serum aldosterone level, he was diagnosed as having PHA. However, the electrolyte abnormality was spontaneously resolved (Fig. 1) , and he was discharged from hospital on day 76. During the infantile period, he showed poor feeding and failure to thrive. Whenever he had a common cold, he developed severe dehydration and had to be admitted to hospital. The results of all blood examinations showed mild hypokalemia (minimum potassium level: 3.1 mEq/l) and metabolic alkalosis. Detection of nephrocalcinosis by means of ultrasonography when he was 5 years old led to a diagnosis of BS. But his electrolyte abnormality was quite mild, and his failure to thrive was also mild; therefore, he continued to be observed without receiving any treatment.
At the time of this report, the boy's height was 165 cm (−1.0 SD) and intelligence and blood pressure were normal. He had normal potassium (3.6 mEq/l) and sodium (137 mEq/l) levels, but metabolic alkalosis (HCO 3 − :
28 mEq/l) persisted. In spite of normal blood pressure, he showed high plasma renin activity (37.0 ng/ml per h; normal: 0.3-2.9) and serum aldosterone (184 ng/dl: normal: 3.9-30.7) levels. His serum calcium (8.6 mg/dl) and magnesium (2.2 mg/dl, normal 1.7-2.3) levels were normal, as was his renal function (blood urea nitrogen: 10.2 mg/dl: Cr: 0.89 mg/dl). He showed hypercalciuria (urinary Ca/Cr: 0.8 mg/mg; normal: 0.1-0.3). These findings led to suspicion of type II BS, and he was therefore referred to our division for genetic diagnosis.
Genetic analysis and results
Having obtained informed consent from the patient and his parents, we performed genetic analysis of the SLC12A1, Fig. 1 Plasma potassium and sodium levels by postnatal day. GI therapy: Glucose-insulin therapy KCNJ1, and CLCNKB genes [2] [3] [4] . Genomic DNA was extracted from leukocytes with the standard phenol-chloroform extraction method. We selected previously described primers, which amplify all exons and exon-intron boundaries. Polymerase chain reaction (PCR) was followed by purification of the PCR products and direct sequencing on both strands. Direct sequencing of double-strand DNA fragments of the six genes and all exons was performed with the aid of the PCR primers and an ABI PRISM BigDye Thermal Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) and an ABI model 310 auto sequencer. The result was that a homozygous 1-bp deletion mutation (c.607 del. C in exon 5) in the KCNJ1 gene was detected (Fig. 2) . Both parents were found to carry the heterozygous 1-bp deletion mutation. They showed no apparent clinical symptoms or laboratory data abnormalities.
Discussion
This report describes a patient with neonatal BS accompanied by severe hyperkalemia, hyponatremia, and metabolic acidosis evident in the early neonatal period and who was initially diagnosed with PHA. In childhood, however, he showed mild hypokalemia, which became normal in adolescence, when hypercalciuria and nephrocalcinosis were observed. When genetic analysis detected a homozygous 1-bp deletion mutation (c.607 del. C in exon 5) in the KCNJ1 gene, this patient's disease was diagnosed as type II BS (OMIM 241200). Some authors have reported that the majority of patients with type II BS show hyperkalemia and hyponatremia and some of them metabolic acidosis in the early neonatal period [8] [9] [10] . After the neonatal period, serum potassium levels are not as low as in type I BS, even though most of the previously reported type II BS patients were taking indomethacin [8, 10] . Jeck et al. reported that of ten patients with type II BS, three showed signs of transitory and marked hyperkalemia in the neonatal period and two did not show hypokalemic alkalosis at any time [8] . Peters et al. reported that nine of 14 patients had hyperkalemia and that the younger the gestational age, the higher the maximal serum potassium level is likely to be. Moreover, they found that the patients showed no transitory hyperkalemia after 32 weeks of gestation. They also detected a significant negative correlation between gestational age and maximal serum potassium. Moreover, three of their patients were suspected of having PHA [9] . Finer et al. reported on 12 cases with hyperkalemia whose plasma potassium levels Fig. 2 Detection of KCNJ1 mutation by direct sequencing. Homozygous 1-bp deletion mutation (c.607 del. C in exon 5) was detected. Both parents were found to carry the heterozygous 1-bp deletion mutation. The bottom shows wild-type sequence that includes c.607 C peaked generally at the third day of life and then gradually decreased to normal values. However, one of their patients died of ventricular arrhythmias with a peak potassium level of 10.5 mEq/l. In addition, they reported that, although some of the patients showed normal potassium levels during childhood, most of them were taking indomethacin [10] . It has been suggested that the higher baseline plasma K level usually observed in premature neonates contributes to a reduction in Na-K-ATPase activity, with Landau stating in a review article that transient hyperkalemia in the patients with type II BS may be the cause of a gestational-age-related decrease in Na-K-ATPase activity. This transient hyperkalemia would then be resolved, as the transporter activity increases during postnatal maturation [11] . On the other hand, urinary K excretion is derived almost entirely from K secretion in the connecting tubule and cortical collecting duct (CCD) [12] . In contrast to the high rates of K secretion observed in CCDs isolated from adult animals, neonatal animals show no significant K transport until 3 weeks of gestation. These findings indicate that the low rates of urinary K secretion characteristic of the newborn kidney are due, at least in part, to a low secretory capacity of the CCD [13] . It has further been reported by several authors that an increase in the tubular fluid flow rate in CCD stimulates K secretion (reviewed in [14] ). Woda et al. reported that the absence of flow-dependent K secretion early in life is due to the developmental regulation of maxi-K-channel expression [15] . The K retention characteristic of the neonatal kidney is due, in part, to a paucity of maxi-Kchannel expression in the CCD. Thus, in addition to loss of the ROMK channel function and decreased Na-K-ATPase activity, weak expression of the maxi-K channel may lead to the severe transient hyperkalemia seen in type II BS.
During the infantile period, patients with type II BS develop hypokalemia owing to increased renal potassium excretion, which is believed to be attributable to a functional loss of ROMK channel activity in the thick ascending limb (TAL), which in turn may lead to the inactivation of NKCC2. Recently, Bailey et al. reported that this renal potassium loss in type II BS patients is due to both reduced reabsorption in the TAL and K secretion by maxi-K channels in the late distal tubule. This was confirmed in ROMK-deficient mice [16] . In this way, the maxi-K channel may make a substantial contribution to this unique clinical course of type II BS.
The KCNJ1 gene is thought to produce several isoforms of ROMK, with exon 5 being common to all of these isoforms and encoding the majority of the channel proteins [17] . Mutations in exon 5 may therefore cause the transient hyperkalemia in the early neonate period or the milder serum electrolyte abnormality after the neonatal period in type II BS compared with that seen in type I BS. The mutation identified in our patient was the homozygous 1-bp deletion that causes the frame shift from 203 amino acid (aa). This mutation is also thought to lead to dysfunction in the ATP-binding regulatory domain (aa 190-240) and C terminus. Several point mutations in this area have already been the subject of reports that also clearly explained the mechanism leading to ROMK dysfunction. The ATPbinding regulatory domain may eliminate protein kinase A (PKA) phosphorylation, which was found to lower affinity for phosphatidylinositol lipids and reduce the probability of the channel remaining open [18, 19] . It has further been reported that mutations in the C terminus change the structural arrangement of the pH sensor and make the pH gating more alkaline [20] .
Our patient was 18 years old at the time of this report. Appearance and intelligence were normal, and height was almost normal. His potassium level was normal, and he showed mild alkalosis, hypercalciuria, and nephrocalcinosis. Although he has never received any treatment, his clinical course after childhood was very mild. The unique clinical findings of our case are that in the early postnatal period, he was diagnosed as PHA because of hypokalemia and metabolic acidosis, whereas during adolescence, he showed hypercalciuria and nephrocalcinosis with normal potassium levels without having received any treatment.
In conclusion, we should be aware of the possibility of this unusual course of type II BS and perform genetic analysis to determine whether suspicion of type II BS is warranted.
